The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) Neal, J. W., Pennell, N. A., Govindan, R., Lanuti, M., Rosovsky, R. P., Heist, R. S., Shaw, A. T., Temel, J. S., Muzikansky, A., Janne, P. A., Lynch, T. J., Azzoli, C. G., Sequist, L. V. AMER SOC CLINICAL ONCOLOGY. 2012

View details for Web of Science ID 000318009801374